Deal Snapshot
Sesen Bio to Merge with Carisma Therapeutics in All-Stock Transaction
Thursday 22 September 2022

US-based late-stage clinical company Sesen Bio, Inc. (NASDAQ: SESN) has agreed to merge with US-based clinical stage biopharmaceutical company Carisma Therapeutics Inc. in an all-stock transaction, the company said.

The combined company will focus on the advancement of Carisma's proprietary cell therapy platform that utilises engineered macrophages and monocytes to potentially transform the treatment of cancer and other serious disorders.

Date Published: 22/09/2022